
News and Press Releases
Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
Psyence Australia Pty Ltd, has partnered with iNGENū Pty Ltd (iNGENū) to conduct Psyence’s previously announced clinical trial in palliative care. iNGENū is an Australian based, globally focused Contract Research Organization (CRO) with extensive experience working in the psychedelic pharmaceutical drug development and clinical research industry.
Psyence and Eden Labs Announce Extraction and Product Development Collaboration
Psyence is pleased to announce that it has entered into a partnership with Eden Labs LLC, (“Eden Labs”) a product development and extraction technology company that has developed intellectual property and methodologies around the extraction of psilocybin-yielding mushrooms.
Psyence Group Completes Export Of Pharma Grade Psilocybin Extract To UK
Psyence announce that it has exported purified pharmaceutical grade psilocybin mushroom extract to its Contract Development & Manufacturing Organisation (“CDMO”) partner in the United Kingdom.
Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
Psyence & Newcourt have entered into a definitive business combination agreement (the “Business Combination Agreement”) on January 9, 2023 with Psyence Biomed Corp (“Psyence Biomed”), a wholly owned subsidiary of Psyence, to create a public company (the “Combined Company”) leveraging natural psilocybin in the treatment of palliative care (the “Business Combination”). Psyence Biomed is Psyence’s clinical trial division.
Psyence Signs Letter of Intent with Australian CRO iNGENū
Psyence announce it has signed a Letter of Intent (LOI) with Contract Research Organisation (CRO) iNGENū to execute Psyence’s strategy of clinical development in palliative care. iNGENū is an Australian full-service CRO specialising in clinical trials for psychoactive pharmaceuticals.
Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
The agreement expands on an existing partnership and grants Psyence the right to commercialize Filament’s natural psilocybin drug candidate PEX010 25mg within palliative care
Psyence Group Announces Closing Of Second Tranche Of Private Placement And Appointment Of Strategic Advisor
Psyence Group Announces Closing Of Second Tranche Of Private Placement And Appointment Of Strategic Advisor Toronto, Canada/ December 14, 2022 / Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life [...]
GOODMIND Available For Sale In The United Kingdom And Europe – Exclusive Distribution Agreement Concluded With This Works.
Psyence is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), entered into an exclusive distribution agreement with This Works Products Limited (“This Works”) for the distribution and sale of the joint venture’s functional mushroom brand, GOODMINDTM, in the United Kingdom and Europe.
Psyence Group Announces Strategic Private Placement
Psyence announce that it has received subscription agreements for gross proceeds of CAD$1.22 million from a consortium led by Brandon Kerzner, a member of the globally recognised Kerzner family. Brandon has a focus on investing in technology and life science advancement industries.